AR and neoplasm: Within prostate cancer, longitudinal sampling of treatment‐resistant disease combined with spatial transcriptomics and immunohistochemistry has been used to help understand mechanisms for treatment resistance, such as the location of active androgen receptors relative to the tumour cell nuclei following androgen deprivation therapy [61].